UroGen Pharma Q3 EPS $(0.03) Misses $0.14 Estimate, Sales $89.001M Miss $89.918M Estimate
Benzinga Newsdesk 5 hours ago
NewsEarningsEarnings Misses
UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.14 by 121.43 percent. This is a 95.65 percent increase over losses of $(0.69) per share from
UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.14 by 121.43 percent. This is a 95.65 percent increase over losses of $(0.69) per share from the same period last year. The company reported quarterly sales of $89.001 million which missed the analyst consensus estimate of $89.918 million by 1.02 percent. This is a 223.64 percent increase over sales of $27.500 million the same period last year.